More than 25 percent of babies are born via cesarean section in many countries, and such births are associated with an increased risk of obesity, autoimmune diseases or asthma. However, the scientific foundation for making the leap to microbirthing as a protective measure against that risk is shaky, according to the editorial’s authors.
“We lack that certainty at present,” they wrote. “Newborns may develop severe infections from exposure to vaginal commensals and pathogens, which the mother may carry asymptomatically … We are aware of only one current clinical trial investigating vaginal seeding, but the primary outcome is alteration of the neonatal microbiota rather than a clinical outcome, and it excludes women with vaginal carriage of potential pathogens.”
Beyond fostering an increased awareness of the risks that come along with vaginal seeding, the authors suggest that other influential factors on infants’ bacterial populations, such as encouraging breast feeding and avoiding unnecessary antibiotic use, could have greater impact on health outcomes later in life.
More articles on infection control:
Researchers restore microbiomes of C-section infants via bacterial swab
Checking in after an outbreak: Q&A with Dr. Andrew Ross on how Virginia Mason overhauled its medical scope reprocessing practices
Microbial genomics company uBiome partners with CDC to investigate HAIs: 3 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
